Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study

• Published in: The Journal of urology Vol. 147; no. 2; p. 371
• Main Authors: Melekos, M D, Dauaher, H, Fokaefs, E, Barbalias, G
• Format: Journal Article
• Language: English
• Published: United States 01.02.1992
• Subjects: Administration, Intravesical; Aged; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - pathology; Carcinoma, Transitional Cell - prevention & control; Carcinoma, Transitional Cell - surgery; Epirubicin - administration & dosage; Epirubicin - adverse effects; Female; Humans; Male; Neoplasm Recurrence, Local - prevention & control; Prospective Studies; Urinary Bladder Neoplasms - mortality; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - prevention & control; Urinary Bladder Neoplasms - surgery
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(17)37240-3

A controlled prospective study in 65 patients was done to evaluate the efficacy of intravesical epirubicin administration as prophylactic treatment in regard to the pattern of tumor recurrences after complete endoscopic resection of superficial transitional cell carcinoma of the bladder. Intravesical instillations of the drug were given weekly for 6 consecutive weeks and to the responders an intermittent maintenance therapy was administered for the first 2 years after each followup examination. Of the patients treated prophylactically with epirubicin 37% had recurrence within a total of 1,136 patient-months compared to 55% of the controls who were followed for a total of 436 months, a difference that was not statistically significant (p greater than 0.05). However, examining the results in another manner, the control patients demonstrated a significantly shorter mean interval to recurrence and higher recurrent tumor rate per 100 patient-months. To clarify further the efficacy of epirubicin therapy, comparisons of the treatment outcome according to several tumor factors were done. These comparisons revealed a significant benefit for those who received epirubicin with respect to history of tumor recurrences and multiplicity at presentation. Drug-induced toxicity was acceptable. Our study suggests that epirubicin is safe and effective against the recurrence of superficial bladder cancer.